The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease
Abstract
The aim of the study was to provide evidence‐based recommendations for the management of early (uncomplicated) Parkinson's disease (PD), based on a review of the literature. Uncomplicated PD refers to patients suffering from the classical motor syndrome of PD only, without treatment‐induced motor complications and without neuropsychiatric or autonomic problems. MEDLINE, Cochrane Library and International Network of Agencies for Health Technology Assessment (INAHTA) database literature searches were conducted. National guidelines were requested from all European Federation of Neurological Societies (EFNS) societies. Non‐European guidelines were searched for using MEDLINE. Part I of the guidelines deals with prevention of disease progression, symptomatic treatment of motor features (parkinsonism), and prevention of motor and neuropsychiatric complications of therapy. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (good practice point) is made.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–318 of 318
Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms
Ceravolo, R., Nuti, A., Piccinni, A., Agnello, G., Bellini, G., Gambaccini, G., Osso, L. D., Murri, L., & Bonuccelli, U. (2000) · Neurology · doi:10.1212/wnl.55.8.1216 · Cited by 128
Self-citationRisperidone for hallucinations in levodopa-treated Parkinson's disease patients
Meco, G., Alessandria, A., Bonifati, V., & Giustini, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92511-9 · Cited by 127
Lisuride, a dopamine agonist in the treatment of early Parkinson's disease
Rinne, U. K. (1989) · Neurology · doi:10.1212/wnl.39.3.336 · Cited by 127
Quetiapine improves psychotic symptoms and cognition in Parkinson's disease
Juncos, J. L., Roberts, V. J., Evatt, M. L., Jewart, R. D., Wood, C. D., Potter, L. S., Jou, H.-C., & Yeung, P. P. (2004) · Movement Disorders · doi:10.1002/mds.10620 · Cited by 126
Factor, S. A., Friedman, J. H., Lannon, M. C., Oakes, D., Bourgeois, K. A., & The Parkinson Study Group (2001) · Movement Disorders · doi:10.1002/1531-8257(200101)16:1<135::aid-mds1006>3.0.co;2-q · Cited by 122
Apomorphine‐induced penile erections in Parkinson's disease
O’Sullivan, J. D., & Hughes, A. J. (1998) · Movement Disorders · doi:10.1002/mds.870130326 · Cited by 120
Horn, G. V., Schiess, M. C., & Koller, W. C. (2000) · Neurology · doi:10.1212/wnl.55.1.156 · Cited by 119
Zesiewicz, T. A., Helal, M., & Hauser, R. A. (2000) · Movement Disorders · doi:10.1002/1531-8257(200003)15:2<305::aid-mds1015>3.0.co;2-w · Cited by 119
Therapies for depression in Parkinson's disease
Ghazi‐Noori, S., Chung, T. H., Deane, K. H., Rickards, H. E., & Clarke, C. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003465 · Cited by 117
Systematic review of paramedical therapies for Parkinson's disease
Deane, K. H., Ellis‐Hill, C., Jones, D. E., Whurr, R., Ben‐Shlomo, Y., Playford, E. D., & Clarke, C. E. (2002) · Movement Disorders · doi:10.1002/mds.10197 · Cited by 113
Reddy, S., Factor, S. A., Molho, E., & Feustel, P. J. (2002) · Movement Disorders · doi:10.1002/mds.10176 · Cited by 113
Quetiapine for Psychosis in Parkinson's Disease Versus Dementia With Lewy Bodies
Fernandez, H. H., Trieschmann, M. E., Burke, M. A., et al. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0608 · Cited by 112
Tolerability of paroxetine in Parkinson's disease: A prospective study
Tesei, S., Antonini, A., Canesi, M., Zecchinelli, A., Mariani, C. B., & Pezzoli, G. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5<986::aid-mds1034>3.0.co;2-i · Cited by 110
Dupont, E., Andersen, A., Boas, J., et al. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb00163.x · Cited by 108
Does selegiline modify the progression of early Parkinson's disease? Results from a five‐year study
Larsen, J. O., Boas, J., Erdal, J. E., & Norwegian‐Danish Study Group (1999) · European Journal of Neurology · doi:10.1046/j.1468-1331.1999.650539.x · Cited by 106
Self-citationBeneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease
Suchowersky, O., Furtado, S., & Rohs, G. (1995) · Movement Disorders · doi:10.1002/mds.870100318 · Cited by 106
Grosset, K. A., Needleman, F., Macphee, G. J. A., & Grosset, D. G. (2004) · Movement Disorders · doi:10.1002/mds.20210 · Cited by 105
Benztropine versus clozapine for the treatment of tremor in Parkinson's disease
Friedman, J. H., Koller, W. C., Lannon, M. C., Busenbark, K. L., Swanson‐Hyland, E., & Smith, D. (1997) · Neurology · doi:10.1212/wnl.48.4.1077 · Cited by 105
Evaluation of a modified inverted walking stick as a treatment for Parkinsonian freezing episodes
Dietz, M. A., Goetz, C. G., & Stebbins, G. T. (1990) · Movement Disorders · doi:10.1002/mds.870050311 · Cited by 105
Agid, Y., Bonnet, A. M., Pollak, P., Signoret, J. L., & Lhermitte, F. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91003-1 · Cited by 103
Improvement of voicing in patients with Parkinson’s disease by speech therapy
Swart, B. J. M. D., Willemse, S. C., Maassen, B., & Horstink, M. W. I. M. (2003) · Neurology · doi:10.1212/01.wnl.0000044480.95458.56 · Cited by 102
Self-citationPergolide monotherapy in the treatment of early PD
Barone, P., Bravi, D., Bermejo‐Pareja, F., Marconi, R., Kulisevsky, J., Malagù, S., Weiser, R., Rost, N. S., & the Pergolide Monotherapy Study Group (1999) · Neurology · doi:10.1212/wnl.53.3.573 · Cited by 102
Environmental risk factors of young onset Parkinson's disease: a case-control study
Tsai, C. H., Lo, S. K., See, L., Chen, H. Z., Chen, R., Weng, Y.-H., Chang, F., & Lu, C. (2002) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(02)00027-6 · Cited by 102
Physiotherapy for Parkinson's disease: a comparison of techniques
Deane, K. H., Jones, D. E., Ellis‐Hill, C., Clarke, C. E., Playford, E. D., & Ben‐Shlomo, Y. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002815 · Cited by 102
Comparison of pergolide and bromocriptine therapy in parkinsonism
LeWitt, P. A., Ward, C. D., Larsen, T., Raphaelson, M. I., Newman, R. P., Foster, N. L., Dambrosia, J. M., & Calne, D. B. (1983) · Neurology · doi:10.1212/wnl.33.8.1009 · Cited by 101
Kaňovský, P., Kubová, D., Bareš, M., Hortová, H., Streitová, H., Rektor, I., & Znojil, V. (2002) · Movement Disorders · doi:10.1002/mds.1276 · Cited by 99
Dopamine and cognitive function
Pillon, B., Czernecki, V., & Dubois, B. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200312002-00004 · Cited by 98
Does levodopa alter depression and psychopathology in Parkinsonism patients?
Marsh, G. G., & Markham, C. H. (1973) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.36.6.925 · Cited by 98
The Benefits of Group Occupational Therapy for Patients With Parkinson’s Disease
Gauthier, L., Dalziel, S., & Gauthier, S. G. (1987) · American Journal of Occupational Therapy · doi:10.5014/ajot.41.6.360 · Cited by 98
Effect of practice on performance of a skilled motor task in patients with Parkinson's disease.
Soliveri, P., Brown, R. G., Jahanshahi, M., & MARSDEN, C. D. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.6.454 · Cited by 95
Ben‐Shlomo, Y., Churchyard, A., Head, J. A., Hurwitz, B., Overstall, P. W., Ockelford, J., & Lees, A. J. (1998) · BMJ · doi:10.1136/bmj.316.7139.1191 · Cited by 95
Self-citationTraining improves the speed of aimed movements in Parkinson's disease
Platz, T., Brown, R. G., & Marsden, C. D. (1998) · Brain · doi:10.1093/brain/121.3.505 · Cited by 93
Non motor off in Parkinson's disease: Non motor off in PD
Raudino, F. (2001) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2001.00357.x · Cited by 92
Cubo, E., Leurgans, S. E., & Goetz, C. G. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.05.001 · Cited by 92
Rehabilitation and Parkinson's disease
Formisano, R., Pratesi, L., Modarelli, F., Bonifati, V., & Meco, G. (2020) · Journal of Rehabilitation Medicine · doi:10.2340/1650197799224157160 · Cited by 91
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease
Deane, K. H., Spieker, S., & Clarke, C. E. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004554.pub2 · Cited by 90
Maricle, R. A., Nutt, J. G., & Carter, J. H. (1995) · Movement Disorders · doi:10.1002/mds.870100316 · Cited by 89
Werber, E. A., & Rabey, J. M. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100008 · Cited by 89
Does Nefazodone Improve Both Depression and Parkinson Disease? A Pilot Randomized Trial
Ávila, A., Cardona, X., Martín‐Baranera, M., Maho, P., González‐Sastre, F., & Bello, J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000088908.24613.db · Cited by 88
Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease
Dewey, R. B., & O’Suilleabhain, P. E. (2000) · Neurology · doi:10.1212/wnl.55.11.1753 · Cited by 88
Mohr, E., Mendis, T., Hildebrand, K., & Deyn, P. P. D. (2000) · Movement Disorders · doi:10.1002/1531-8257(200011)15:6<1230::aid-mds1026>3.0.co;2-9 · Cited by 86
Sudden uncontrollable somnolence and medication use in Parkinson disease.
Avorn, J., Schneeweiss, S., Sudarsky, L., Benner, J., Kiyota, Y., Levin, R., & Glynn, R. (2005) · Archives of Neurology · doi:10.1001/archneur.62.8.1242 · Cited by 86
Does levodopa therapy delay death in Parkinson's disease? A review of the evidence
Clarke, C. E. (1995) · Movement Disorders · doi:10.1002/mds.870100303 · Cited by 84
A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease
Jankovic, J. J., & Hunter, C. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00040-2 · Cited by 83
Clozapine in Parkinson's disease tremor: Effects of acute and chronic administration
Bonuccelli, U., Ceravolo, R., Salvetti, S., D’Avino, C., Dotto, P. D., Rossi, G., & Murri, L. (1997) · Neurology · doi:10.1212/wnl.49.6.1587 · Cited by 83
Self-citationRaffaele, R., Vecchio, I., Giammusso, B., Morgia, G., Brunetto, M. B., & Rampello, L. (2002) · European Urology · doi:10.1016/s0302-2838(02)00054-4 · Cited by 82
Koller, W. C., Lees, A. J., Doder, M., Hely, M. A., & the Tolcapone/Pergolide Study Group (2001) · Movement Disorders · doi:10.1002/mds.1175 · Cited by 81
Self-citationSymptomatic effect of selegiline in de novo parkinsonian patients
Allain, H., Pollak, P., & Neukirch, H. C. (1993) · Movement Disorders · doi:10.1002/mds.870080508 · Cited by 81
Fields, J. A., & Tröster, A. I. (2000) · Brain and Cognition · doi:10.1006/brcg.1999.1104 · Cited by 80
Katayama, Y., Kasai, M., Oshima, H., Fukaya, C., Yamamoto, T., Ogawa, K., & Mizutani, T. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.95.2.0213 · Cited by 78
Przuntek, H., Welzel, D., Gerlach, M., Bl�mner, E., Danielczyk, W., Kaiser, H. J., Kraus, P. H., Letzel, H., Riederer, P. F., & �berla, K. (1996) · Journal of Neural Transmission · doi:10.1007/bf01271230 · Cited by 77
Levodopa prolongs life expectancy and is non-toxic to substantia nigra
Rajput, A. H. (2001) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00023-2 · Cited by 75
Effect of Reboxetine on Depression in Parkinson’s Disease Patients
Lemke, M. R. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0405 · Cited by 74
Morbidity and mortality following pallidotomy in Parkinson’s disease: A systematic review
de Bie, R. M. A., de Haan, R. J., Schuurman, P. R., Esselink, R. A. J., Bosch, D. A., & Speelman, J. D. (2002) · Neurology · doi:10.1212/wnl.58.7.1008 · Cited by 73
Herd, C. P., Tomlinson, C. L., Deane, K. H., Brady, M., Smith, C. H., Sackley, C. M., & Clarke, C. E. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002812 · Cited by 72
Katzenschlager, R., Manson, A. J., Evans, A. H., Watt, H., & Lees, A. J. (2004) · PubMed · Cited by 71
Self-citationNon-pharmacological therapies for dysphagia in Parkinson's disease
Deane, K. H., Whurr, R., Clarke, C. E., Playford, E. D., & Ben‐Shlomo, Y. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002816 · Cited by 68
Ahlskog, J. E., Muenter, M. D., McManis, P. G., BELL, G. N., & Bailey, P. A. (1988) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)62690-1 · Cited by 68
Risperidone treatment of drug-related psychosis in patients with parkinsonism
Leopold, N. A. (2000) · Movement Disorders · doi:10.1002/1531-8257(200003)15:2<301::aid-mds1014>3.0.co;2-2 · Cited by 67
Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson??s Disease
Etminan, M., Samii, A., Takkouche, B., & Rochon, P. A. (2001) · Drug Safety · doi:10.2165/00002018-200124110-00007 · Cited by 67
Gelenberg, A. J. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0101 · Cited by 67
Brunt, E. R., Brooks, D. J., Korczyn, A. D., Montastruc, J., & Stocchi, F. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200040 · Cited by 66
Levodopa Infusion Therapy in Parkinson Disease: State of the Art in 2004
Nyholm, D., & Aquilonius, S. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000144041.28224.b7 · Cited by 66
Protein Redistribution Diet Remains Effective in Patients With Fluctuating Parkinsonism
Karstaedt, P. J., & Pincus, J. H. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530260049018 · Cited by 66
Stereotactic neurosurgery for tremor
Speelman, J. D., Schuurman, P. R., de Bie, R. M. A., Esselink, R. A. J., & Bosch, D. A. (2002) · Movement Disorders · doi:10.1002/mds.10147 · Cited by 63
Fahn, S., & ISGREEN, W. P. (1975) · Neurology · doi:10.1212/wnl.25.8.695 · Cited by 62
Dam, M., Tonin, P., Casson, S., Bracco, F., Piron, L., Pizzolato, G., & Battistin, L. (1996) · PubMed · Cited by 61
Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease
Parkes, J. D., Baxter, R. C., MARSDEN, C. D., et al. (1974) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.37.4.422 · Cited by 61
Bullock, R. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x16777 · Cited by 61
Bromocriptine and domperidone in the treatment of Parkinson disease
Quinn, N. P., Illas, A., Lhermitte, F., & Agid, Y. (1981) · Neurology · doi:10.1212/wnl.31.6.662 · Cited by 60
Lisuride versus bromocriptine treatment in Parkinson disease: A double‐blind study
LeWitt, P. A., Gopinathan, G. V., Ward, C. D., Sanes, J. N., Dambrosia, J. M., Durso, R., & Calne, D. B. (1982) · Neurology · doi:10.1212/wnl.32.1.69 · Cited by 60
Ziegler, M., Castro‐Caldas, A., Signore, S. D., & Rascol, O. (2003) · Movement Disorders · doi:10.1002/mds.10359 · Cited by 60
Self-citationLevodopa-Induced Postural Hypotension
Hoehn, M. M. M. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490430072013 · Cited by 59
Diagnosis and treatment of Parkinson's disease: a systematic review of the literature.
Levine, C. B., Fahrbach, K. R., Siderowf, A. D., Estok, R. P., Ludensky, V. M., & Ross, S. D. (2003) · PubMed · Cited by 59
Imbalance of Brain Monoamines and Clinical Disorders
Hornykiewicz, O. (1982) · Progress in brain research · doi:10.1016/s0079-6123(08)64212-0 · Cited by 57
Tolcapone added to levodopa in stable parkinsonian patients: A double‐blind placebo‐controlled study
Dupont, E., Burgunder, J., Findley, L. J. J., Olsson, J., Dorflinger, E. E., & Tolcapone In Parkinson's Disease Study Group Ii (TIPS Ii) (1997) · Movement Disorders · doi:10.1002/mds.870120615 · Cited by 57
Adjuvant Therapy of Parkinsonian Tremor
Koller, W. C., & Herbster, G. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520210023013 · Cited by 57
Motor fluctuations in Parkinson’s disease
Denny, A. P., & Behari, M. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00052-0 · Cited by 57
Moclobemide and selegeline in the treatment of depression in Parkinson's disease
Steur, E. N. H. J., & Ballering, L. A. P. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.63.4.547 · Cited by 57
Activity and acceptability of piribedil in Parkinson's disease: a multicentre study
Rondot, P., & Ziegler, M. (1992) · Journal of Neurology · doi:10.1007/bf00819564 · Cited by 54
Postural Tremor of Parkinsonʼs Disease
Henderson, J. M., Yiannikas, C., Morris, J. G., Einstein, R., Jackson, D., & Byth, K. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199406000-00007 · Cited by 54
Cognitive functioning after pallidotomy for refractory Parkinson's disease
Perrine, K. R., Dogali, M., Fazzini, E. P., Sterio, D., Kolodny, E. H., Eidelberg, D., Devinsky, O., & Berić, A. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.2.150 · Cited by 51
Outcome of unilateral pallidotomy in advanced Parkinson's disease: cohort study of 32 patients
de Bie, R. M. A. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.3.375 · Cited by 51
Tröster, A. I., Woods, S. P., Fields, J. A., Hanisch, C., & Beatty, W. W. (2002) · Brain and Cognition · doi:10.1016/s0278-2626(02)00504-3 · Cited by 49
Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients
Pierelli, F., Adipietro, A., Soldati, G., Fattapposta, F., Pozzessere, G., & Scoppetta, C. (1998) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb05955.x · Cited by 48
Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson?s disease (MSPD)
Morrison, C. E., Borod, J. C., Brin, M. F., H�lbig, T. D., & Olanow, C. W. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0145-8 · Cited by 46
Jankovic, J. J., Schwartz, K. S., & van der Linden, C. (1989) · Movement Disorders · doi:10.1002/mds.870040403 · Cited by 45
Neuropsychological and psychiatric sequelae of pallidotomy for PD
Green, J., McDonald, W. M., Vitek, J. L., Haber, M., Barnhart, H. X., Bakay, R. A. E., Evatt, M. L., Freeman, A., Wahlay, N., Triche, S. D., et al. (2002) · Neurology · doi:10.1212/wnl.58.6.858 · Cited by 45
Protein Redistribution Diet and Antiparkinsonian Response to Levodopa
Bracco, F., Malesani, R., Saladini, M., et al. (2008) · European Neurology · doi:10.1159/000116649 · Cited by 44
Beta-blocker therapy for tremor in Parkinson's disease
Crosby, N. J., Deane, K. H., & Clarke, C. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003361 · Cited by 43
Allain, H., Destée, A., Petit, H., et al. (2000) · European Neurology · doi:10.1159/000008188 · Cited by 43
High-Dose Ropinirole in Advanced Parkinson's Disease With Severe Dyskinesias
Cristina, S., Zangaglia, R., Mancini, F., Martignoni, E., Nappi, G., & Pacchetti, C. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200305000-00008 · Cited by 43
Sivertsen, B., Dupont, E., Mikkelsen, B. O., et al. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb01794.x · Cited by 43
Rascol, O., Pathak, A., Bagheri, H., & Montastruc, J. (2004) · Movement Disorders · doi:10.1002/mds.20202 · Cited by 42
Self-citationPezzoli, G., Martignoni, E., Pacchetti, C., Angeleri, V. A., Lamberti, P., MURATORIO, A., Bonuccelli, U., Mari, M. D., Foschi, N., Cossutta, E., et al. (1995) · Neurology · doi:10.1212/wnl.45.3_suppl_3.s22 · Cited by 42
Self-citationPeripheral beta‐adrenergic blockade treatment of parkinsonian tremor
Foster, N. L., Newman, R. P., LeWitt, P. A., Gillespie, M., Larsen, T., & Chase, T. N. (1984) · Annals of Neurology · doi:10.1002/ana.410160412 · Cited by 41
Morrison, C. E., Borod, J. C., Brin, M. F., Raskin, S. A., Germano, I. M., Weisz, D. J., & Cw, O. (2000) · PubMed · Cited by 40
Tolcapone, bromocriptine, and Parkinson's disease
Agid, Y., Destée, A., Durif, F., Jl, M., & P Pollak, O. B. O. T. F. G. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63511-8 · Cited by 38
Switching and combining dopamine agonists
Reichmann, H., Herting, B., M�ller, A., & Sommer, U. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0081-z · Cited by 35
A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
Kulisevsky, J., López‐Villegas, D., García‐Sánchez, C., Barbanoj, M. J., Gironell, A., & Pascual‐Sedano, B. (1998) · PubMed · Cited by 35
Pohanka, M., Kaňovský, P., Bareš, M., Pulkrábek, J., & Rektor, I. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00820.x · Cited by 34
Montastruc, J., Desboeuf, K., Lapeyre‐Mestre, M., Sénard, J., Rascol, O., & Brefel‐Courbon, C. (2001) · Movement Disorders · doi:10.1002/mds.1093 · Cited by 32
Self-citationBromocriptine versus levodopa in early Parkinson's disease
van Hilten, Ramaker, C. C., Stowe, R. L., & Ives, N. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002258.pub2 · Cited by 30
LIEBERMAN, A. N., Gopinathan, G., MILLER, E., Neophytides, A. N., Baumann, G., & Chin, L. (2008) · European Neurology · doi:10.1159/000117314 · Cited by 27
Non-pharmacological interventions
Lips, P. T. A. M., & Ooms, M. E. (2000) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2000.0073 · Cited by 26
Role of surgery in the treatment of motor complications
Metman, L. V., & O’Leary, S. T. (2005) · Movement Disorders · doi:10.1002/mds.20480 · Cited by 26
Przuntek, H., & Kuhn, W. (1987) · PubMed · Cited by 25
Boas, J., Worm-Petersen, J., Dupont, E., Mikkelsen, B. O., & Wermuth, L. (1996) · European Journal of Neurology · doi:10.1111/j.1468-1331.1996.tb00188.x · Cited by 24
Giménez-Roldán, S., Esteban, E. M., & Mateo, D. (2001) · Clinical Neuropharmacology · doi:10.1097/00002826-200111000-00006 · Cited by 22
Deep brain stimulation for movement disorders
Deuschl, G., Volkmann, J., & Krack, P. (2002) · Movement Disorders · doi:10.1002/mds.10135 · Cited by 18
Self-citationShort-Term Memory in Parkinsonʼs Disease After Withdrawal of Long-Term Anticholinergic Therapy
van Herwaarden, G., Berger, H. J. C., & Horstink, M. W. I. M. (1993) · Clinical Neuropharmacology · doi:10.1097/00002826-199310000-00006 · Cited by 18
Self-citationSelective Serotonin Reuptake Inhibitors (SSRIs)
Gitlin, M. J. (2007) · Elsevier eBooks · doi:10.1016/b978-012373947-6.00638-3 · Cited by 16
Cardiac arrhythmias reported during treatment with cisapride
Tooley, P. J. H., Vervaet, P., & Wager, E. (1999) · Pharmacoepidemiology and Drug Safety · Cited by 15
KR 339 IN THE TREATMENT OF PARKINSONIAN TREMOR
Iivanainen, M. V. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1974.tb02794.x · Cited by 15
Orthostatic hypotension in multiple system atrophy
Riley, D. E. (2000) · Current Treatment Options in Neurology · doi:10.1007/s11940-000-0005-2 · Cited by 14
Diagnosis and Treatment of Parkinson's Disease: A Systematic Review of the Literature: Summary
Levine, C. C., Fahrbach, K., Siderowf, A., Estok, R. P., Ludensky, V. M., & Ross, S. D. (2003) · Cited by 11
(2001) · doi:10.1002/1531-8257(200101)16:1<79::aid-mds1013>3.0.co;2-h
Cited by
Neurostimulation for Parkinson's Disease with Early Motor Complications
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205158 · Cited by 1,430
Self-citationKehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 881
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Self-citationRandomized trial of safinamide add‐on to levodopa in Parkinson's disease with motor fluctuations
Borgohain, R., Szasz, J., Stanzione, P., Meshram, C., Bhatt, M., Chirilineau, D., Stocchi, F., Lucini, V., Giuliani, R., Forrest, E., et al. (2014) · Movement Disorders · doi:10.1002/mds.25751 · Cited by 293
Drug-Induced Urinary Retention: Incidence, Management and Prevention
Verhamme, K. M. C., Sturkenboom, M. C. J. M., Stricker, B. H. C., & Bosch, R. (2008) · Drug Safety · doi:10.2165/00002018-200831050-00002 · Cited by 264
Metadata
- Authors
- Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., Rascol, O., & Sampaio, C.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2006-10-13
- Volume
- 13
- Issue
- 11
- Pages
- 1170-1185
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2155114981
- Cited by
- 297
- References
- 318
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.